A meta-analysis of EGFR-TKI/EGFR-TKI+KLT for the treatment of patients with stage III/IV NSCLC showed that compared with EGFR-TKI alone, KLT plus EGFR-TKI significantly improved the disease control rate (DCR), objective response rate (ORR), Karnofsky performance status (KPS), enhanced patient immunity, increased percentage of CD4+ T cells, CD4+/CD8+ ratio, and percentage of NK cells. Here, CD4 is linked to non-small cell lung carcinoma.